Oncology/Hematology
Leukemia
More in Leukemia
Treatment tied to higher recovery odds and faster time to kidney recovery
FDA boxed warning led to multiple studies on the issue in 2024
News, features, and commentary about cancer-related issues
3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone
News, features, and commentary about cancer-related issues
"I thought he was helping me"
Ponatinib-blinatumomab led to durable remissions without transplant in most, but 13% relapsed
But no overall survival benefit seen in confirmatory trial
Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more
AMPLIFY trial paves the way for FDA approval of acalabrutinib plus venetoclax
Complete responses seen in 43% of patients in expansion cohort of EPCORE CLL-1 study
Cytokine release syndrome developed in all patients, including grade 3/4 events in nearly half
Blinatumomab consolidation reduced risk of relapse by 61% versus chemotherapy alone
Little is being done to curb the risk
